GE Healthcare agrees to $30 million settlement

Pharmaceutical giant GE Healthcare will pay $30 million to the U.S. Department of Justice to settle claims in a case filed by a Michigan salesman, alleging one of its companies marketed a diagnostic drug used in cardiology tests as one that could be diluted and stretched to more patients than intended.

For patients, the diluted product resulted in more false positives during cardiology tests and exposed them to additional and unnecessary testing, Navarro said.